• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

7.350 -0.500 (-6.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 02, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
December 01, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
November 06, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
October 23, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
August 25, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
August 07, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
July 31, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
June 03, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Details for Analyst & Investor Day
May 20, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
May 08, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
May 01, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
April 17, 2025
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xeris Announces Changes to Its Board of Directors
March 28, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
March 17, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
March 06, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025
February 27, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
February 24, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris to Participate in Upcoming Investor Conferences
February 05, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
January 10, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 06, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From Xeris Biopharma
Via Business Wire
News headline image
Xeris Biopharma Reports Third Quarter 2024 Financial Results
November 08, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
October 31, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 04, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris to Participate in Upcoming Investor Conferences
August 22, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Reports Second Quarter 2024 Financial Results
August 08, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Announces CEO Succession Plan
July 08, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 03, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap